Publication | Open Access

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Fasted StateRandomized Phase 1MedicineMetronomic TherapyPharmacologyPathologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyAnaplastic Lymphoma KinaseLung CancerMolecular Oncology